Abstract:Non-alcoholic fatty liver disease (NAFLD) is manifested by hepatic steatosis, insulin resistance, hepatocyte death, and systemic inflammation. Obesity induces steatosis and chronic inflammation in the liver. However, the precise mechanism underlying hepatic steatosis in the setting of obesity remains unclear. Here, we report studies that address this question. After 14 weeks on a high-fat diet (HFD) with high sucrose, C57BL/6 mice revealed a phenotype of liver steatosis. Transcriptional profiling analysis of the liver tissues was performed using RNA sequencing (RNA-seq). Our RNA-seq data revealed 692 differentially expressed genes involved in processes of lipid metabolism, oxidative stress, immune responses, and cell proliferation. Notably, the gene encoding neutral sphingomyelinase, SMPD3, was predominantly upregulated in the liver tissues of the mice displaying a phenotype of steatosis. Moreover, nSMase2 activity was elevated in these tissues of the liver. Pharmacological and genetic inhibition of nSMase2 prevented intracellular lipid accumulation and TNFα-induced inflammation in in-vitro HepG2-steatosis cellular model. Furthermore, nSMase2 inhibition ameliorates oxidative damage by rescuing PPARα and preventing cell death associated with high glucose/oleic acid-induced fat accumulation in HepG2 cells. Collectively, our findings highlight the prominent role of nSMase2 in hepatic steatosis, which could serve as a potential therapeutic target for NAFLD and other hepatic steatosis-linked disorders.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of neutral sphingomyelinase 2 (nSMase2) in non - alcoholic fatty liver disease (NAFLD) and to study the possibility of it as a therapeutic target. Specifically, through high - fat diet (HFD) - induced mouse models and in vitro cell experiments, the study explored the mechanism of action of nSMase2 in liver steatosis and inflammation. The study found that the increase in nSMase2 activity is related to liver fat accumulation and inflammatory response, and inhibiting nSMase2 can reduce fat accumulation and inflammation, thus may become a new strategy for treating NAFLD. ### Research Background Non - alcoholic fatty liver disease (NAFLD) is a common chronic liver disease, mainly manifested as liver steatosis, insulin resistance, hepatocyte death and systemic inflammation. Obesity induces liver steatosis and chronic inflammation, but its exact mechanism is still unclear. This paper explored the role of nSMase2 in NAFLD through a mouse model fed with a high - fat diet (HFD). ### Main Findings 1. **Mouse Model**: - After 14 weeks of high - fat diet (HFD) feeding, the mice showed obvious liver steatosis, increased liver weight, and histological examination showed macrovesicular and microvesicular steatosis and lobular inflammation. - Immunohistochemical staining showed significant macrophage infiltration and lipid accumulation in the livers of HFD - fed mice. 2. **Transcriptome Analysis**: - RNA sequencing results showed that there were 692 differentially expressed genes in the livers of HFD - fed mice, of which 510 genes were up - regulated and 672 genes were down - regulated. - Gene Ontology (GO) enrichment analysis indicated that the up - regulated genes were related to lipid metabolism, oxidative stress, immune response, cell proliferation and apoptosis; the down - regulated genes were related to triglyceride synthesis, gluconeogenesis, glucose response, inflammatory response and endoplasmic reticulum response. - KEGG pathway analysis showed that the up - regulated genes were related to cholesterol metabolism, MAPK signaling pathway, steroid biosynthesis process, NF - κB and Wnt signaling pathways and bile secretion; the down - regulated genes were related to metabolism, AMPK signaling pathway, fatty acid degradation, PPAR and PI3K - Akt signaling pathways, insulin resistance and alcoholic liver disease. - The most significantly enriched differentially expressed genes were related to cholesterol metabolism, reactive oxygen species, apoptosis, ATP response, lipid metabolism and fatty acid metabolism. - In particular, the Smpd3 gene encoding nSMase2 was significantly up - regulated in steatotic livers. 3. **In Vitro Experiments**: - Using the HepG2 cell model to simulate steatosis, it was found that after high - glucose and oleic acid treatment, intracellular lipid accumulation increased significantly and TNF - α levels increased. - Inhibiting nSMase2 can reduce intracellular lipid accumulation and TNF - α - induced inflammatory response, improve oxidative damage, and prevent high - glucose/oleic acid - induced fat accumulation and cell death. ### Conclusion This study revealed the important role of nSMase2 in non - alcoholic fatty liver disease, especially its key role in liver fat accumulation and inflammation. Inhibiting nSMase2 may be a potential target for the treatment of NAFLD.

Neutral Sphingomyelinase 2 Inhibition Limits Hepatic Steatosis and Inflammation

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Regulated translocation of neutral sphingomyelinase-2 to the plasma membrane drives insulin resistance in steatotic hepatocytes

The Role of Neutral Sphingomyelinase-2 (NSM2) in the Control of Neutral Lipid Storage in T Cells

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1

Sphingomyelin Synthase 2 Activity and Liver Steatosis

Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α

Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis

Sphingomyelin Synthase–related Protein SMSr is a Phosphatidylethanolamine Phospholipase C That Promotes Nonalcoholic Fatty Liver Disease

Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis

Deletion of Sphingosine Kinase 1 Ameliorates Hepatic Steatosis in Diet-Induced Obese Mice: Role of PPARγ.

The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis

α,β-Amyrin prevents steatosis and insulin resistance in a high-fat diet-induced mouse model of NAFLD via the AMPK-mTORC1-SREBP1 signaling mechanism

Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis

Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α

Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice

Hepatocellular Cystathionine Γ Lyase/hydrogen Sulfide Attenuates Nonalcoholic Fatty Liver Disease by Activating Farnesoid X Receptor

Sphingomyelin Synthase 2 Activity and Liver Steatosis an Effect of Ceramide-Mediated Proliferator-Activated Receptor Γ 2 Suppression

SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice

Hydrogen Sulfide Attenuates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Inhibiting Apoptosis and Promoting Autophagy via Reactive Oxygen Species/Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Signaling Pathway